Osimertinib, or, Tagrisso

Osimertinib, or, Tagrisso

Patient-friendly review of Osimertinib, also known by its trade name Tagrisso, used in treating EGFR mutation-positive metastatic non-small cell lung cancer.

It was approved by the FDA in 2015 also for use as an EGFR kinase inhibitor in the treatment for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

Approved by

the Medical Board. 

Click Here

The EGFR gene is responsible for the production of the EGFR proteins which tells cells to divide. This means that when there is a mutation in the gene, it can cause the function of the protein to change and promote further growth of cells, even in cancerous cells. The cancer drug is used in targeted therapy to target the mutated gene within the cancer cell and blocks it.

The recommended dosage is 80 mg, taken orally without food until toxicity or disease progression.

Common side effects include fatigue, dry skin, diarrhea and decreased appetite.

Precautions: 

  • Cardiomyopathy (disease of the heart muscles)
  • pneumonitis (inflammation in the lungs)
  • Embryo-fetal toxicity
  • Inflammation of the eye(s)

Other articles that you may find interesting are:

  1. A diet for Chemotherapy
  2. Immunotherapy overview
  3. A to Z Guide to Complementary Therapies

Go to: Return to the CANCERactive drug list

Health Experts
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.